Lactobacillus plantarum per Irritable Bowel Syndrome (IBS)
B Evidenze Almeno un trial randomizzato lo supporta, con risultati per lo più coerenti.Reduces abdominal pain and bloating in IBS. Multiple RCTs show significant improvement in global IBS symptom scores. Strain-specific evidence for 299v is relatively strong.
In sintesi
Reduces abdominal pain and bloating in IBS. Multiple RCTs show significant improvement in global IBS symptom scores. Strain-specific evidence for 299v is relatively strong.
Key Study Findings
Popolazione: patients with irritable bowel syndrome
Popolazione: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Popolazione: female rats with water avoidance stress-induced IBS-D model
Popolazione: C. rodentium + WAS IBS mouse model
Popolazione: Zymosan-induced IBS mouse model
Popolazione: IBD patients with IBS symptoms in remission
Key Statistics
5
Studi
800
Partecipanti
Positive
Grado
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosaggi di uso comune
- general:
- 10-20 billion CFU/day
- ibssupport:
- 10 billion CFU/day (299v strain) for 4 weeks minimum
Limite massimo: Well-tolerated up to 20 billion CFU/day in clinical trials
Dosaggi studiati nella ricerca
| Dosaggio | Durata | Effetto | N |
|---|---|---|---|
| None | -- | Positive | 3154 |
| None | -- | Positive | -- |
| Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 | 4 weeks | Positive | 25 |
| 1e9 CFU/day + GOS 10 g/L | -- | Positive | -- |
| None | -- | Positive | -- |
| None | 12 weeks | Neutral | 61 |
| None | 8 weeks | Positive | 1098 |
| 10 μg | 6 weeks | Positive | 246 |
Momento migliore per l'assunzione: On an empty stomach or before meals
Safety & Side Effects
Effetti collaterali segnalati
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional loose stools
- ⚠ Histamine-related symptoms in sensitive individuals (histamine-producing species)
- ⚠ Very rare: bacteremia in immunocompromised individuals
Interazioni note
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
- ● Histamine-intolerance medications (L. plantarum may produce biogenic amines)
Livello di assunzione massimo tollerabile: Well-tolerated up to 20 billion CFU/day in clinical trials
Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.
Frequently Asked Questions
Does Lactobacillus plantarum help with Irritable Bowel Syndrome (IBS)?
How much Lactobacillus plantarum should I take for Irritable Bowel Syndrome (IBS)?
Are there side effects of Lactobacillus plantarum?
How strong is the evidence for Lactobacillus plantarum and Irritable Bowel Syndrome (IBS)?
Related Evidence
Altri ingredienti per Irritable Bowel Syndrome (IBS)
References
- [1] Roman Maslennikov et al.. J Clin Med. 2026. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. doi:10.3390/jcm15031152 PubMed
- [2] Theodore Rokkas et al.. Eur J Gastroenterol Hepatol. 2026. Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable bowel syndrome: a systematic review … doi:10.1097/MEG.0000000000003062 PubMed
- [3] Nazila Dardmeh et al.. J Sci Food Agric. 2026. Effect of probiotic administration of Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 on metabolic profiles in an … doi:10.1002/jsfa.70190 PubMed
- [4] Qi Yao et al.. Nutrients. 2025. Lactobacillus plantarum and Galacto-Oligosaccharides Synbiotic Relieve Irritable Bowel Syndrome by Reshaping Gut Microbiota and Attenuating Mast Cell Hyperactivation. doi:10.3390/nu17101670 PubMed
- [5] Anne Fennessy et al.. World J Gastrointest Pharmacol Ther. 2025. Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation … doi:10.4292/wjgpt.v16.i2.101268 PubMed
- [6] Lim Song et al.. J Microbiol Biotechnol. 2025. Synergistic Modulation of the Gut-Brain-Immune Axis by a Dual Lactobacillus Combination in a Murine IBS Model. doi:10.4014/jmb.2507.07018 PubMed
- [7] L Drago et al.. Benef Microbes. 2025. A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults. doi:10.1163/18762891-bja00097 PubMed
- [8] Hongyun Zhang et al.. Food Funct. 2024. Lactobacillus plantarum AR495 improves colonic transport hyperactivity in irritable bowel syndrome through tryptophan metabolism. doi:10.1039/d4fo01087f PubMed
- [9] Pauline Jouët et al.. Minerva Gastroenterol (Torino). 2024. Probiotics plus vitamin D in irritable bowel syndrome: a prospective multicentric non-interventional study. doi:10.23736/S2724-5985.24.03581-2 PubMed
- [10] Young Hoon Chang et al.. J Neurogastroenterol Motil. 2024. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. doi:10.5056/jnm23036 PubMed
- [11] Olga Biskou et al.. Front Med (Lausanne). 2024. ReFerm®: a postbiotic fermented oat gruel composition is reducing mast cell degranulation in the colon of patients with irritable bowel … doi:10.3389/fmed.2024.1408623 PubMed
- [12] Sarvesh V Surve et al.. J Appl Microbiol. 2024. Laboratory domestication of Lactiplantibacillus plantarum alters some phenotypic traits but causes non-novel genomic impact. doi:10.1093/jambio/lxae035 PubMed
- [13] Vivek C Goodoory et al.. Gastroenterology. 2023. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. doi:10.1053/j.gastro.2023.07.018 PubMed
- [14] Vivek C Goodoory et al.. Drugs. 2023. Antibiotics and Probiotics for Irritable Bowel Syndrome. doi:10.1007/s40265-023-01871-y PubMed
- [15] Hee-Young Kim et al.. Food Nutr Res. 2022. Kimchi improves irritable bowel syndrome: results of a randomized, double-blind placebo-controlled study. doi:10.29219/fnr.v66.8268 PubMed
- [16] Seung Yong Shin et al.. J Neurogastroenterol Motil. 2022. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: … doi:10.5056/jnm21202 PubMed
- [17] Kyoungmi Jung et al.. Nutrients. 2022. Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study. doi:10.3390/nu14102015 PubMed
- [18] Olga Bednarska et al.. Front Nutr. 2022. A postbiotic fermented oat gruel may have a beneficial effect on the colonic mucosal barrier in patients with irritable bowel … doi:10.3389/fnut.2022.1004084 PubMed
- [19] Moeen-Ul-Haq et al.. J Pak Med Assoc. 2022. Role of Lactobacillus plantarum 299v versus Placebo in symptomatic improvement of irritable bowel syndrome patients. doi:10.47391/JPMA.0758 PubMed
- [20] E Arvidsson Nordström et al.. Benef Microbes. 2021. Lactiplantibacillus plantarum 299v (LP299V®): three decades of research. doi:10.3920/BM2020.0191 PubMed
- [21] Bo Yang et al.. Front Immunol. 2021. Lactobacillus plantarum CCFM1143 Alleviates Chronic Diarrhea via Inflammation Regulation and Gut Microbiota Modulation: A Double-Blind, Randomized, Placebo-Controlled Study. doi:10.3389/fimmu.2021.746585 PubMed
- [22] Haiyan Xu et al.. Eur J Nutr. 2021. Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome. doi:10.1007/s00394-020-02437-4 PubMed
- [23] Luisa Marras et al.. Microorganisms. 2021. The Role of Bifidobacteria in Predictive and Preventive Medicine: A Focus on Eczema and Hypercholesterolemia. doi:10.3390/microorganisms9040836 PubMed
- [24] Diego A Barraza-Ortiz et al.. Dig Dis. 2021. Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: … doi:10.1159/000510950 PubMed
- [25] Yang Liu et al.. Food Funct. 2021. Evidence from comparative genomic analyses indicating that Lactobacillus-mediated irritable bowel syndrome alleviation is mediated by conjugated linoleic acid synthesis. doi:10.1039/d0fo02616f PubMed
- [26] Prapaporn Boonma et al.. Front Pain Res (Lausanne). 2021. Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome. doi:10.3389/fpain.2021.691689 PubMed
- [27] Wojciech Marlicz et al.. Prz Gastroenterol. 2021. Probiotics in irritable bowel syndrome - is the quest for the right strain over? Rapid review of existing guidelines and … doi:10.5114/pg.2021.111766 PubMed
- [28] Karolina Kaźmierczak-Siedlecka et al.. Cent Eur J Immunol. 2020. The role of Lactobacillus plantarum 299v in supporting treatment of selected diseases. doi:10.5114/ceji.2020.101515 PubMed
- [29] Alberto Saccarello et al.. Prim Care Companion CNS Disord. 2020. Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study. doi:10.4088/PCC.19m02578 PubMed
- [30] Karolina Kaźmierczak-Siedlecka et al.. Nutr J. 2020. The use of Lactobacillus plantarum 299v (DSM 9843) in cancer patients receiving home enteral nutrition - study protocol for a … doi:10.1186/s12937-020-00598-w PubMed
- [31] K Kaźmierczak-Siedlecka et al.. Eur Rev Med Pharmacol Sci. 2020. Effects of 4 weeks of Lactobacillus plantarum 299v supplementation on nutritional status, enteral nutrition tolerance, and quality of life in … doi:10.26355/eurrev_202009_23059 PubMed
- [32] Yen-Wenn Liu et al.. Probiotics Antimicrob Proteins. 2020. Lactobacillus plantarum PS128 Ameliorated Visceral Hypersensitivity in Rats Through the Gut-Brain Axis. doi:10.1007/s12602-019-09595-w PubMed
- [33] Konstantinos Leventogiannis et al.. Probiotics Antimicrob Proteins. 2019. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. doi:10.1007/s12602-018-9401-3 PubMed
- [34] Ewa Pejcz et al.. Foods. 2019. Technological Methods for Reducing the Content of Fructan in Wheat Bread. doi:10.3390/foods8120663 PubMed
- [35] Luigi Bonavina et al.. Acta Biomed. 2019. Abincol® (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01), an oral nutraceutical, pragmatic use in patients with … doi:10.23750/abm.v90i7-S.8649 PubMed
- [36] Elsa Sandberg Nielsen et al.. Food Funct. 2018. Lacto-fermented sauerkraut improves symptoms in IBS patients independent of product pasteurisation - a pilot study. doi:10.1039/c8fo00968f PubMed
- [37] Jin Young Yoon et al.. Dig Dis Sci. 2018. Probiotics Ameliorate Stool Consistency in Patients with Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Study. doi:10.1007/s10620-018-5139-8 PubMed
- [38] I Presti et al.. Appl Microbiol Biotechnol. 2015. Evaluation of the probiotic properties of new Lactobacillus and Bifidobacterium strains and their in vitro effect. doi:10.1007/s00253-015-6482-8 PubMed
- [39] Cheryl Stevenson et al.. Nutrition. 2014. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. doi:10.1016/j.nut.2014.02.010 PubMed
- [40] María Ortiz-Lucas et al.. Rev Esp Enferm Dig. 2013. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. doi:10.4321/s1130-01082013000100005 PubMed
- [41] Marina L Ritchie et al.. PLoS One. 2012. A meta-analysis of probiotic efficacy for gastrointestinal diseases. doi:10.1371/journal.pone.0034938 PubMed
- [42] Philippe Ducrotté et al.. World J Gastroenterol. 2012. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. doi:10.3748/wjg.v18.i30.4012 PubMed
- [43] Bong Ki Cha et al.. J Clin Gastroenterol. 2012. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, … doi:10.1097/MCG.0b013e31823712b1 PubMed
- [44] Wojciech Marlicz et al.. Pol Merkur Lekarski. 2012. [Irritable bowel syndrome--irritable bowel or irritable mind?]. PubMed
- [45] M Bixquert Jiménez. Rev Esp Enferm Dig. 2009. Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? doi:10.4321/s1130-01082009000800006 PubMed
- [46] Martin H Floch. J Clin Gastroenterol. 2005. Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature. doi:10.1097/01.mcg.0000156104.67505.5b PubMed
- [47] H-J Krammer et al.. Z Gastroenterol. 2005. [Probiotics as therapeutic agents in irritable bowel syndrome]. doi:10.1055/s-2004-813934 PubMed
- [48] Alfredo Saggioro. J Clin Gastroenterol. 2004. Probiotics in the treatment of irritable bowel syndrome. doi:10.1097/01.mcg.0000129271.98814.e2 PubMed
- [49] Anthony G Wynne et al.. Anaerobe. 2004. An in vitro assessment of the effects of broad-spectrum antibiotics on the human gut microflora and concomitant isolation of a … doi:10.1016/j.anaerobe.2004.03.002 PubMed
- [50] S Sen et al.. Dig Dis Sci. 2002. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. doi:10.1023/a:1020597001460 PubMed
- [51] Joel A. Sach et al.. Curr Treat Options Gastroenterol. 2002. Irritable Bowel Syndrome. doi:10.1007/s11938-002-0049-3 PubMed
- [52] K Niedzielin et al.. Eur J Gastroenterol Hepatol. 2001. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. doi:10.1097/00042737-200110000-00004 PubMed
- [53] S Nobaek et al.. Am J Gastroenterol. 2000. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. doi:10.1111/j.1572-0241.2000.02015.x PubMed
Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.